PHILADELPHIA, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it has been named one of the Philadelphia Business Journal’s “Best Places to Work” for 2017, in the large company category.
“As a pioneering gene therapy company with deep roots in West Philadelphia, we are proud to be named one of the 2017 ‘Best Places to Work’ by the Philadelphia Business Journal,” said Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics. “With more than 300 employees, we have doubled our employee count every year since our founding in 2013, and it is satisfying to see that our mission continues to inspire employees. The strength and resilience of the patients and families we aim to serve are what motivates us to create the path toward a world where no life is limited by genetic disease.”
The Philadelphia Business Journal selected winners based on employee responses to an engagement survey conducted by Quantum Workplace, an independent employee feedback software company. The “Best Places to Work” survey measures key areas such as work environment, professional development and embracing change and new ideas.
To learn more about Spark Therapeutics and current job openings, visit www.sparktx.com or follow Spark Therapeutics on LinkedIn.
About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver, such as hemophilia. Spark Therapeutics has ongoing clinical trials investigating gene therapies in hemophilia A and B. SPK-8011 is in an ongoing, dose-escalation Phase 1/2 clinical trial as a potential one-time therapy for hemophilia A. The company retains full global commercialization rights to the SPK-FVIII program. SPK-9001, which has received both breakthrough therapy and orphan product designations by FDA, and access to the PRIority MEdicines (PRIME) Program by EMA, is in a Phase 1/2 clinical trial for hemophilia B and is being developed in collaboration with Pfizer. Our most advanced investigational candidate, with proposed trade name LUXTURNA™ (voretigene neparvovec), is currently under Priority Review with FDA for the treatment of biallelic RPE65-mediated IRD and has been designated as a drug for a rare pediatric disease. The marketing authorization application for LUXTURNA has been submitted to EMA for the treatment of vision loss due to Leber congenital amaurosis or retinitis pigmentosa caused by confirmed biallelic RPE65 mutations. LUXTURNA has received breakthrough therapy and orphan product designations from FDA and orphan product designations from EMA. The pipeline also includes SPK-7001 in an ongoing Phase 1/2 clinical trial for choroideremia. For more information on our pipeline, visit www.sparktx.com.
Investor Relations Contact:
Monique da SilvaMonique.firstname.lastname@example.org
Spark Therapeutics, Inc.